June 4, 2023

 Hilton Boston/Woburn

    2 Forbes Road, Woburn, MA 01801, United States

Countdown Timer

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

ABOUT CHINA FOCUS
China has embraced a vigorously growing healthcare market in the past decade. Ever since joining ICH in 2017, China has seen increased clinical trials and accelerated new drug and device approval. For biotech and medtech companies outside of China, you need to find the right partners and the right resources to bring your products to China, in order to adapt to difference in culture, regulation, reimbursement, etc. In the meantime, Chinese biotechs are actively seeking global market entry opportunities and oversea partners.

China Focus is a partnering forum designed to provide a meaningful platform to inform, inspire, and foster cross-border partnership in life science and healthcare.

Who should attend
  • Investors (VC, PE, investment bank, etc.)
  • Life science innovators and entrepreneurs
  • Biotech & big pharma
  • Medtech (device and diagnostics) manufacturers and distributors
  • Service providers (law firm, financial advisory, regulatory consulting, CRO, CDMO, etc.)
  • Healthcare providers
Main Topics
  • Cross-border investment: money from the East and the West
  • Innovations going to China: regulation, market access, manufacturing and distribution
  • Chinese innovations going west: partnership for capital and market access in the U.S.
What you can get
  • Learn about Chinese life science and healthcare industry
  • Hear about the latest Chinese regulatory reforms and implications
  • Meet with the decision makers in the industry
  • Initiate business conversations that otherwise difficult to start
REGISTRATION
Agenda

08:00-09:00

Check in

09:00-09:10

Opening Remarks

Larry Cai, Venture Partner of MybioCapital

09:10-09:30

Keynote: Capturing innovative and market opportunities in China

Helen Chen, Global Sector Co-Head for Healthcare&Greater China Managing Partner, L.E.K

BD&Investment and Financing Sub-venue

09:30-10:10

Panel: Discussion on International Cooperation Opportunities for China's Original Research and Innovative Drugs

Moderator: Larry Cai, Venture Partner of MybioCapital
Guests:
Jenny Yang, Head of external innovation Asia Pacific,Novo Nordisk
John Lu, President and CEO, HebeCell
Brian Yang, VP&Head of Corporate Strategy and BD, ArkBio
Leo Bao, Venture Partner of MybioCapital
Bin Chen, Vice President of MedChem, XtalPi

10:10-10:50

Panel: China Pharmaceutical BD International Cooperation Successful Experience Sharing

Moderator: Sara Chen, VP of Business Development, NeoLogics
Guests: Weihao Xu, CFO&CBO, Harbour BioMed
Joan Shen, Founder&CEO, NeuShen Therapeutics
Ben Zhao, Founder&President, Haichang Biotech
Ping Cao, Chief Business Officer/VP of Business Development, Henlius
Kelvin Shao, VP of Business Development, Kexing Biopharma

10:50-11:00

Do's and Don't's in cross border BD collaborations

Wendy Pan, Partner, GOODWIN

11:10-11:40

Real world case experience sharing

Moderator: Wendy Pan, Partner, GOODWIN
Guests: Larry Cai, Venture Partner of MybioCapital
Seamus Jiang – U.S./China Cross-border Deals Leader Managing Director, PwC US

11:40-13:30

Lunch Break

Enmore Biologics Development Summit ( Organizer: Enmore Healthcare & Wuxi Biologics )

13:30-14:00

Interpretation of Product Access Policy in the US Market

Wesely, CEO, CUBIO

14:00-14:30

Accelerated CMC development from DNA to IND

Sherry Gu, WuxiBiologics US&EU CMC Management SVP

14:30-15:00

An Intergraded Overview on High Concentration Drug Product Development and manufacturing-from FormulationtoAutoinjectorse

Jeremy Guo, Wuxi Biologics, Drug product development and DP manufacturing VP

15:00-15:30

Industrialization of Chemically Defined(CD) Media: Development, Production Strategies, and Case Study Analysis

Yantao Wang Shanghai Maibang (Medium Bank) Biotechnology Chairman and CEO

15:30-16:30

Panel: Discussion on the futureR&D and CMC trend of biopharmaceuticals

Moderator: Jijie Gu, Wuxi Biologics CSO
Guests: Sherry Gu, Wuxi Biologics US& EU CMC Management SVP
Wei Gan, Zenas Bio SVP
Stacy Price, Chief Technology&Manufacturing Officer, Invivyd

16:30-17:00

Fourth revolutionary wave of Biologics Manufacturing

Peng Jiao,CEO of BiBo Biopharma Engineering Co.,Ltd.

17:00-17:30

M4: A novel therapeutic oligonucleotide solution to obesity-induced disease and muscle wasting

Luke Chen, Founder&CEO, xNA Biotechnology

17:30-18:30

Cocktail Party

09:30-17:30       1 ON 1 MEETING

FEATURED SPEAKERS

Helen Chen

Global Sector Co-Head for Healthcare&Greater China Managing Partner, L.E.K

Weihao Xu

CFO&CBO, Harbour BioMed

John Lu

President and CEO, HebeCell

Ping Cao

Chief Business Officer/VP of Business Development
Henlius

Jeremy Guo

Wuxi Biologics, Drug product development and DP manufacturing VP

Wendy Pan

Partner, GOODWIN

Larry Cai

Venture Partner
MybioCapital

Brian Yang

VP&Head of Corporate Strategy and BD, ArkBio

Sara Chen

VP of Business Development
NeoLogics

Ben Zhao

Founder&President
Haichang Biotech

Jijie Gu

Chief Scientific Officer and Executive Vice President
WuXi Biologics

Kelvin Shao

VP of Business Development
Kexing Biopharma

Sherry Gu

SVP, CMC Management
WuXi Biologics

Jenny Yang

Head of external innovation Asia Pacific,Novo Nordisk

Leo Bao

Venture Partner of MybioCapital

Bin Chen

Vice President of MedChem, XtalPi

Joan Shen

Founder&CEO, NeuShen Therapeutics

Seamus Jiang

U.S./China Cross-border Deals Leader Managing Director, PwC US

Wesley Okeke

CEO, CUBIO

Wei Gan

Zenas Bio SVP

Peng Jiao

CEO, BiBo Biopharma Engineering

Yantao Wang

Shanghai Maibang (Medium Bank)
Biotechnology Chairman and CEO

Luke Chen

Founder&CEO, xNA Biotechnology

organizer

 past Media partner
ATTENDEE DEMOGRAPHICS
at Previous China Focus Events
Contact Us
Registration, Sponsorship and Collaboration (China)

Xiaojia Zhang

[email protected]

Registration, Sponsorship and Collaboration(Overseas)

Vicent Zhao

[email protected]

Address: 2 Forbes Road, Woburn, MA 01801, United States

14 + 4 =